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Introduction

Probably every ageRt uaed in the treatment of
diaea•• haa·aome d1Mdvantagea.

Th••• d.iaadvantagea

may manifest thems�lv�• ·in a variety of waya.

�n•ulin,

tor example, in large doe•s will produce an inaulin �
■hock or coma.

Mercury and Arsenic will produce a

nephritis and diarrhea.

Morphine will cause nausea,

vomiting and re•piratory paralyaia.

From theae

e.xamplea it can be aeen that there 1• a wide variety
in the type of aymptoma that can be produced.

�he purpose of th1a paper 1• to describe the
toxic reaction• resulting from the uae of th•
aultonamidea.

Since the advent of the ■ulfonamidea

aeveral hundred articles have been writt�n c�Dcern
iag aome complication reaulting from one or all of
the aultonamidea.

�ince so many article■ have been

written this paper cannot poaaibly cover them all,
but an attempt will be made at covering the variou•
types of reaction• that have been reported up to
the preaent time.

1.

In th• field. of cl1Utothttra1>7, which ia .almoat
a• old ea the art of medicine itself, a. continuou■
search has been going on for specific drµgs and _
�emedies which could be used in the treatment of
disease.

ln spite of the many years that this search

has been going on up to modern times only a few drugs
worthy of being called specifics had been found.
uong the drugs which were found ,o have ·a specific
action were cinchona or quinine for Malaria, mercury

for syphilis, and ipecac or emetine for various types
of dysentery.

No further noteworthy ad'Tances in

bac�eriology.

Following th• development of

chemotherapy were made until th• development ot
bacteriology s�veral advances were mad� in the

field of chemistry.
Modern chemotherapy dat�s from the timw of
Kbrlich. Ji.hrlich tried many synthetic dyes in

animals with trypansome infections with some degree
of success.

With Shiga in 1904 he developed a

benzedrine dye, trypan red, which was trypanocidal.
A few years later Mesnil and Nicolla developed a
toluidine dye called trypan blue, which was
effective in protozoal infections of doga and

cattle.

During. th1& .perJ.od the parasite of syphilia,
a apiroehete was discovered and Jilirl1ch bes,n hia
ep.o.chal work with the araen1cala.-, deYt.loping in
.19.10 �b•rsan, J:u..a.

.u hnpdred and sixth pre.�r•

t1on, a specific for syphi.11.a.+

·J:b1a _....,__ th� great

est discoYery in chemotherapy in modern times and

is equalled only by the most recent chemotheraputic
agents, the sulfonamides.

_Recently Young, White and Schwartz combined
mercury with fluorescein dye.
known

as

mercUl"ochrome
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Thia preparation was

and was used as an

antiseptic, but it has not lived up to the expecta
tions for internal use.

Another dye, gentian violet,

recently developed by Churehmann is now used external
ly tor bacterial· and fungus infections.
Morgenroth and Levy in 1911, found that optochine,

a�derivative of quinine, was an effective chemo�hera

peutic preparation in the treatment of pneaumonia in
mice, but this preparation has not been aucceasful
because ot the toxicity in effective dosage.
�his covers the most important phas�s of chemo
iherapy up to a few years ago.

�here was some success

in the therapy of protozoa! and metazoil. infections,

but· in ,o far as bacterial infections were concerned,
only successful antiseptics were deYeloped.

(1)

The application of sulf'anilamide and 1ts vari

ous derivatiYes to the treatment of bacterial in

fection• represented a culmination of many attempts
to control these diseases with chemicals since ·t he
dawn of bacteriologic research.

�n 1908, Oelmo

synthesized para amino benzene sulfonamide.

�n the

following year, ttoerlein, Dressel and �othe of the
I. G. Fa�••nindustrie, prepared azo dyes with

aultonamiqe and substituted sulf'onamide groups.
�h•1r aim was to detelop dyes for textile purposti&
and they found that the azo-ault'onamid• compounds
were distinguished by there greater fastness for

washing and milling than those of s�lt'onamide free
products.

�hes• qualities were attributed to the

.intimate union of the protein cells of the wool
and the dye.

This factor may help to explain the

bacteriocidal and toxic retetions of the aulfona
mid•s that will be discusNd later.

It wa� ffl>t until 1933 that the first clinical
report on the use

or aulfonamidea app.eared. in

1935,Domagk stated that Prontos11, a relat1Yelj

4.

non-toxic red dye, when given in small dos�s pre
vented the evolution of otherwise fatal hemolytic
.streptococcal 1n.fections in mice, controlled and
cured chronic streptococcal infections in rabbits,
and .favorabl y in:f"luenced the course o.f staphylo
coccal infections in rabbits, but that the drug was
without effect in the tr•atment of certain pneum.o
coccal and other ,�erimental 1n.fect1ons.

in France, LtTad1t1 and Vaisman, and Nitti
and Bovet began to,,work· with the dyes.

Nit'i1 and

Bovet.diacovered that the action o.f th� dye waa
due to the sulfanilamide group.

The aulfanilamide

alone possessed an amAzing bacteriocidal action.

In England, Colebrook and Kenny confirmed the work

o.f the French investigators.

Since the preparation of sulfanilamide several
hundred sulfonamide compounds have been produced.
Most of these preparations have been o.f no valu�
because of' their toxicity.

However, sulfa

pyrridine, a derivative of sulf'anilamide, was
.found to be more effective in experi•ental pneu.ino
coccie infections than the dull'anilamide its�ll'.
This discovery was msde by L. E. H. Whitby of

I

5.

London.

Another compound, sulfathiezole, was

ayntheaized by Landon and Sjoegren in Sweden �
in 1938 and Qy Fosbinder end Walter; Lott and
Bergeim in the United States in 1939.

In 1940

two new sulfonamides which are of value were
prepared.

These two were aulfaguanidine and

aulfadiazine.

The work on the sul.t'aguanidine

was announced by Marshall at Johns Hopkins
University and that on sulfadiazine was announc
ed by Roblin of the uerican Cyan01ia Coapany.
Sultaauxidine is the latest sulfonamide to be

announced but its worth had not been definitely
proYen.

6.

In the use of sul1'onamides toxic reactions
have taken place.

These toxic reactions or com

plications have involved practically all the

organs and tissues of the body at some time or

other.

With th• different compounds ot this

group various findings have resulted.

SeT6ral

theories have been presented to explain these re
actions but none have been definitely proven.

Shaffer ( 4) in 1939, extended an ea.rly pr ..-

iae that the oxidized derivatives of sulfaniluaide
had a high,oxidizing inteneicy which damaged the
reducing system of bacterial cell■ and ala<>. human
cella.

In this manner, one could explain the

toxic ertecta of the arug on the huaan organism.
Fortunately, the cells of the invaded host can

withstand the injurious effect better than the.

bacteria.

Mellon, Locke, and Shinn (5) in 1940 pro
posed an alternative suggestion that there exists

a s.tepwise production of oxidation products of

aulfanilamide.

In support of this concept they

have indicated that actively growing pathogens

form hydrogen peroxide and that this by-pro4uct

7.
of bacterial metaboliam is normslly removed by
the blood enzyme, ca.talase.

The abnormal accW11ula

tion or hydrogen.peroxide is injurious to the
bacterial cell.

In the presence of suU-anila.mide,

the. oxidative processes going on in the bacterial
cell alter sulfan1lamide and convert it ·into an
antieatalytie agent.

This in turn permits the

accumulation ot hydrogen peroxide .in the cell-en
viroment and growth ot the bacteria is inhibited

by the product of their own metabolism.

In addi

tion to cat·a,laae, it is q�ite likely that other
enzJDle• are adversely affected by the intermediar7
oxidation products of sulfan1lam1de which further
interfere with the metabolism of the bacteria.

A

further step in oxidation results in product toxic
for human cells.
Mann and �ilin (6) in 1940 showed that aulfa
nilamide inhibits the action of an enzyme of the
human body known as carbonic anhydraae •. This
enzyme catalyzes the conversion of carbon dioxide
into bicarbonate.

Since this enzyme 1a related to

the free S02NH2 group of auUanilamide, it is not
affected by aulfapyridine and suUath1azole.

8.

Acidosis is one of the reactions caused by sulfa
nilamide and is quite likely related, in par� to
this inhibitor effect that the drug has on the
enzyme.
Gallagher (7) in 1937 suggested that the

toxic reactions of sultaniluiide were due to a
sensitization.

He based his auggestion on a

case that he had treated with sulfanilamide.

In

1938 he treated a patient with no resulting com
plications.

The next year the same patient was

given sulfanilamide and within thirty aix hours
a morbilliform rash and fever resulted.

Only a

very small dose of sulfanilamide was given the
second time.

In 1940, Davidson and Bullowa (8)

showed that a patient who was sensitized to sulfa
pyridine was also sensitive to ault'athiazole and
sultamethylthiazole.

The patient, however, was not

sensitive to sulfanilamids.

Nelaon (9) in 1942

had a patient who showed sensitivity to all the
sulfonamides with the exception ot sulfapyridine.
Wedum (10) in 1942, reported his results on
some extensive animal experimentation with sulfo
namides.

He tried to find out if the animals could

9.
be sensitized to simple sul1'onamidea.

His results·

showed that the s·ulfonamides alone were, not capable
of producing a sensitization.

WedtDl prfpar·ed hapten

conjugates with egg, beef, liver atrd ··other proteins.
He found that the animals treated with the hapten
conjugates of sulfonamides were cap�bl� of render
ing the animal susceptible to akin teats of the
hapten conjugates but not to skin tests of the

•i�ple sulfonamides were not susceptible to akin
tests of the hapten conjugates of sulfonamides.
The hapten conjugates were called azoproteina.
The explanation of sens1tiT1ty or toxicity is
that the sul1'onamides unite with vatious body
proteins to form antigens.

Thea� in turn

stimulate the formation of antibodies for these
antigens.

When another series of treatment ia

begun with the l'ulfonamides there is another
formation of antigen.

The antibodies already

present react with the newly formed antigen and
produce the toxic reaction.
In 1941, Strauss end Finland (11) reported
on the Yiew that para e.minobenzoic acid may be
an essential metabolite in animals.

By view of

10.
their structural similarity, with this substance,
the aulfonamidea are thus considered to produce
toxic effects in the tissues by replacing para
aminobenzoic acid in the course of metabolic pro
cesses.

Data seems to be consistent with this

hypotheais in so tar as it concerns bacterial
growth.

Strauas and Finland tried to prevent the

toxic reactions ot the aultonamides by giving
large doees of para aminobenzoic acid but this
compound did not overcome.them.
Another theory for the cause of toxic re
actions resulting trom the use of sulfonamides
was offered by Allen (12) in 1940.

He suggest

ed that the toxic reactions were due to the
acetylation of the sul.fonamides.

The more

aeetylaultonamide present, the more marked the
reaction.

In his case report there was an in

crease in gastrointestinal and cerebral symptoms
as the acetylsulfan1lam1de increased in the blood
of his patient who could not excrete the compound
bec�use of a k idney disorder.

Marshall, Cutting

and Emerson (13) produced severe toxic symptoms
in rabbits when the acetyl form exceeded seven to

11.

T

nine milligrams per one

htmdP•u

cub1e.cent1�

meters, but untoward symptoms were not manifest
ed when free sul.1'anilamide was given until a

blood concentration of more than forty milligrams
was obtained.

Thtse workers, also, suggest that

the toxic reactions may be due to an increase ot
the ace\ylated form of the sulfoqamide in the
blood.

Hellwig and Reed (14) showed that sulfa

d1az1ne produced a necrosis in the kidney simi�ar
to mercury poisoning.

There may be, theref�r•, a

direct action ot the sulfonamides on the tissues
ot the body.

ihere has been a great deal ot discussion as
to the· origin of �ne complicat1ona of sulfonamides.
origin and some believe that 1t 1·s of central �1g1n.
In their work on the parenteral use of the sulfo

namides in 1Q42, Ball, Thompson, Wyrena, Harri• and
wilder \15 1 ahowva tnat 1ntre.muscular adm.inistra
t.ion ot ::tulfapyrl.dine decreased the ineidunct:1 ot
d�rmatitis, hematuria, leukopenia and most striking
ly decreased the incidence of nausea and vomiting.

.12

�his decreas• in incidence of nausea and vomiting

tends towards the b�lief that tnti complications are
of local origin.

�he tac� that sulthemoglobin is neceasary for

the destruction of red blood cells was found to b•
false by Richardson (54) in his experimental work
with sulfides an d sulfates.

This would remove

sulfhemoglobin as a cause of toxic reactions in th•
blood.

in 1939, Bigler and Haralambie (16) classified
the complications of the sulfonamides into thre•
group■•

These groups were all•rgic, aild toxic, and

severe toxic ■ymptoms.

�he allergic .man1f�stat1ons

were itching of the skin with urticaria, edema of
the eyelids, lipa, lacr1mat1on and dyspnea.

They

r•port•d, however, that the allergic symptoaa were

rare.

Th• mildly toxic reactions were tne most collUllon
and include nausea, vomiting, abdominal ,ain,
diarrhea, increaaed urination, anorexia, .. 1a1:a.a,
weakness, dizziness, ••rtigo, tinnitus, tingling

sensations, mild psychosis, or disorientation,
f�•-r, raah, acidosis, and cyanoaia.

These aymptoas,

13.
if due to the drug, diaappear promptly on the with
drawal of the drug and may recede ev�n if the drug
is continued.

�he severe toxic reactions, a ccoJWP.ng �o

�igler and Haralambi�, consist of hyperp�r•x1a,
rash, shock, jaundice, aultbemoglob1nem1a,
aethemoglobinemia, anemia, leukopenia, agranulo
cytosia, optic neuritis, peripheral neuritis, and
psychosis.
ihe above classification was �r�pared bofore
suifapyridine and sulf'athiazole came into us�.

To

severe toxic reactions should be added anuria and
the severe dermatoses so that the aboTe claasif1ca
t1on can be applied to all of the aulfonamid8B•
'J.he allorgic r1:1actions,

believe, are just t1arly

man1r�stations of tn� mildly toxic reactions, such
as rash and acidoais, and should be included in
,tha\ group.

Acidoaia and Alkalosi1

Probably the greatest difference of opinion
in tne react.ions ce.usod bi t;he aulfonamid•s n.aa
r�sulted over the acidosis and alkaloais produced
by aulfanilamide.

In 1937 Long and Bliss (17)

14.
reported that certain patients deY�loped ac1d0Mia
durlng 1,n.., coui•i:h, of sulfanilam1dt: therapy.

i:>trauss

and Southworth (18) in 1938 studied the problem and
found that a consistent though variable drop in the
<;02

combining powt:11• of "h-, blood plasma occurr ... d

in 15 conaecutiYe patients who were receiYing
aul.fanilalllide.

They also found a marked increase

in sodium excretion, a marked reduction in the
ammonia output and a sharp increase in the alka
linity·or the urine.

If the fall in th• CO2

combining power was marked under the conditions
of the test, a definlt� hyp�rpnea was noted and
an uncompensated acidosis was established.

In•

order to correct this condition of \lJlCOmpenaated
acidoaia Long and Bliss adYiscd tne rout1n� �se
of sodium bicarbonate with aulfanilamide.
Hartmann, Perley and Barnett (19) (20) had
a different int•r•retation of what happen�d.
�htii showed that af't11:1r th4i:1 initial excr4;1tion ot
sodium and potassium in an alkaline urine there
was a swing back to the acid zone and no aore loas
ot base.

�h•y maintain tha� •ulfanilamide causes

a hy••r•entilation which is followed by the ex-

.15

cretion of bicarbonate 1� the urine and a fall in
the carbon dioxide-.combining power ot
plasma.

"&ht:t

blood

They also found an increaa• in the pH of

th• plasma.

In other words, they believe that a

hJ')terventilation typ• of alkaloaia ha� ro•Ul*ed•

If thia fact were true th•� the administration of

further alkali would increase the aegree of alka
losis.

Mann and a�ilin added to tne contusion with

the fact that the •n�ym•, ca?bonic anhydrase, which
converts carbon dioxide into bicarbonat� i� in-

nib1twd by the action of sulfanilamide.

They point-

ed out that th• inhibitory action of the aulfanil
amide depended on the pr�■onc� of th8 �02NH� group.

Sul.f'athiazole and aulfapyridine do not contain
•this group and, therefore, do not cause an acidosis
or an alka-loaia.

t;yanosia.

Another response to sul.f'onamide therapy that
has cauaed a great difference of opinion is cyanosia.
cyanosis had not been an alarming toxic manifesta
tion and was not an indication for discontinuing

th� drug.

16.

Th•J do not belieYe that methemo

globin or aul1'hemoglob1n is the cause ot the
eyanoaia •

.Hartmann, Pe-rle7, and Barnett ( 19), Wendel
(21), Vigneas, Watson, and Spink (22) are ot the
opinion that the cyanoaia is due to mg�hemoglobin

and not sul1'heaoglob1n.

They haYe shown by spec

trophotometric studies of the blood that there

are no other pigments in th� blood other than

methemoglob1n in quantities laree enough to con
tribute appreciablJ to cyanoaia.

The cyanoais produced b� the ••�hemoglobin

is not serious ·and diaappeara as soon as therapy
ia discontinued.

Long and Blias, Hartmann,

rerley and iS&rn•�t, wendell, and Vigneas, Watson
and Spink haYe shown that intravenous injections
of methylene blue caus�a a diaappcarancg ot

�u•

•Q�hemoglobinelllia and a return to normal or the

spectral distribution curve of the blood •., nowevcr,
this trgatmwnt io not advised.
Th• only aultonamide that produces any
degree ot cyanosia ia aultanilamide.

17.

uaus�a and vomiting.

�ausea and vomiting are the mos t common re
actions caused by the use ot the sulfonamides.
'J.hese SJ]llptoma may bs of such an 1ntenaity as to
require the discontinuation ot the drug.

In other

inatancea it �ay require th� ambulatory pa�i•nt to

be put to bed.

It the Yomiting ia ot a aerioua

degree it may cause an acidosis.

1i

hert1 has bvvn

aom� question aa to whether the nausea and vomiting
are of a central or a local origin.
,3, are ot

Long and Bliss

t.u• o�1nion that the syaptoms are entir�

ly cerebal in origin.

However, Br.own, Thornton, and

Nilson (23) and Hall, �hompaon, wyrene, and Wilder

(15) have shown that the nausea and vomiting ia of

local as •�11 as eerwbral origin •
.Mt>ng, HaYiland, Edward• and Bliaa (27) f'ound
that the more highly integrated the patient ia, the
gr�•��r �nu chance that nausea and yomiting will
occur in the course of' therapy.

Negroes havts littlv

it any d1ff'1cult1 with sultapyridine.
Nausea and vomiting are produced by all ot the

sulfonamides.

:Lhe dtsgr-,e and porcvntago of nauaea

and vomiting vary greatly with the drugs.

�ulf'a-

18.
n1lam1de produces nausoa and vom��ing occasaion
ally and rarely is it ot a serious nature to re

quire the diacontinuvd usG of �h. drug.
in a series or pneumonic patients, Flippin,
Reinhold, and �chwartz t24) found �.nat �ulta
p,r1d1ne caused nausea in 84% of the patients and
�omiting in 60� •

• heau Tom4t�n� a�tacks occurred

more than once, and in some cases the sultapyridinv
had to b� �topp�d.
In th� �am� series by Flippen et al, it was
found that sultathiazol� cauaGu nau�.a in oalJ
�ti% of the cases and Tomiting in 2�.

These

Tomit1ng attacks werb m1ld�r �.ban �buoe ot the
aultapyrid1ne and nausea seldom occurtid between
tbw vomiting. a��acks.

Only 40% ot the patients

taking sulfathiazole TOmitQd moro than once and

80� ot the patients taking aultap,ridinv vomitQa
more than once.

Sulfathiazole had to be dis

continuvd in only on� ca�e because of vomiting
and in eight cases with aultapyridine.
8ultaguand1ne, sulfadiaz�ne, and sulfa
auxidine will cause nausea and vomiting but the
degree or the incidence has not been established

19.

defin�tely.

Finland, Strauss, and Peterson \25J

found in the ca.se of sulftdiasine that nausea and

Tomiting occurred in 9.2%
symptom• -were not severe.

or the cases and the

�- tr&abumt of the nausea and vomiting con

-nst-e, h

the tLevere cases, or diae-ontinuing the

"1:1:rug.. · ·rh&--_c:hanging of one -.uli"onudde · to another ·

=•-,

a-lso-be: �- ae.efit.

Pe�.,-, IUJ-pp;:l.a, _.iC)l•art-z,

--and ·Lockwood ( 26 t reeomended mixing the- a»7il8 �with

.the· use-o.f·-�r-bit-urate-a, dextroise and sodi�

chloride intra·venoua-ly, and the use o.f nicotinic
acid-in large do� .Bro� et al. (23)

a1;rieg the·INlf--•148 with mucilage o.f traga
can:th�nci-=givi11g nieotinic acid.

lia-1-l, WhQJJtp•on,

WyPena.,· ...iuw:LW1ld&r, 'l5-> have--fo�d that parenteral

-�se of the sulfonaaiaea

of nausea and vomiting·considerably •

incidence

20.

Minor Toxic Manifestations.
Long and Bliss (3) listed diarrhea among the
leas common toxic reactions they have encountered.
It may occur with eny of the sulfonamides and ••Y
be associated with nausea and vomiting.

They

noticed frequently bowel movements occurring in
the course of an intravenous injection of
Neoprontosil.

According to Bigler and Haralambie (16J

another reaction that is &S$OCiated witn the
sulfonamides is abdominal pain.

Thia may also

be associated with nausea, vomiting and diarrhea.

Spink (2) found that headache, dizz1neas and

tinnitus occurred rather frequently in individuals
who were receiving the sulfonamides.

lie found

the incidence less with aultathiazole than with

the others.

These C·omplainta-, according to .:;pink,

should cause no concern to the patients kept in
bed.

Mild sedation is of help in these eases.

'!'hese symptoms are of importance in the ambulatory
patients because of the hazard they ofter in
driving automobiles.

21_.

Drug Fever.
A distressing reaction produced by the sulfo
namide drugs is a drug fever.

Drug fever was first

called attention to by HageJ11&n and Blake (28) in
1937.

They reported that in one hundred and thirty

four eases that a teYer developed in 15.6�.

This

unexplained fever developed between the sewenth
and tenth day of tnerapy.

The onset was usually

-abrupt and accompanied �y malaise, nausea, itching,
and tinnitus.

�n nine of these cases a maculo

papular rash with some hemorrhagic lesions devel
oped.

'l.'he fever usually varied but in some cases

it wnet up to 106 degrees.

They also found that

the fever appeared in some instances four or five
days after the drug therapy was discontinued.
'.lhe fever usually lasted from two to four days.
In some cases the fever subsided in apite of
continued adDlinistration of the drug.

Mainzer

(29) in 1938 supported the findings of Hageman
and Blake.

He found that the fever usually

ranged between 101 and 104 degrees.
Drug fever was reported in two cases of

sulfapyr1d1ne oy Pepper, Flippin, �chwartz, and

Lockwood (26).

22.

Flippin, �chwartz and Rose (30)

reported two cases which were thought to be due
to sulfathiazole.

Finland, �trauss, �eterson

(25J reported a drug fever due to sulfadiazine.
There have been no reports in the literature as

yet of drug fever being caused by sulfaguanidine
and aultasuxidine.

There has been some question as to the cause

of Drug Pe'NP-.

O.lla8her ( 7) rep<Wt-ed • caff in

which sulfan1lam1de therapy was started a year

after his firat treatment.

�he first treatment

caused a marked drug fever in ten hours.

Gallagher

believed that the fever was due to a sensitiza

tion.

Davidson and Bullowa {8) also believe that

the fever is due to an acquired sensitivity.

�hey

found a patient who was sensitive to sulfapyrid1ne
and aultametbylthiazole but not to sulfanilamide.
Belson (9) is alao of the opinion that the drug

fever ia due to an acquired sensitivity.

He pre

aented a case in which small doses of sulfatbiazole,
sulfadiazine, and sulfanilamlde cause a rise in
temperature but sulfapP"idine did not.
The·treatment of drug therapy according to
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Hageman and Blake (28) 1s removal or the drug it

the rever gets too high. · .tl.OW&'fer, there 1a always
some difficulty in deciding whether the fever is
due to the drug or to the infection that is being
treated.

One poi�t of diiferentiation is that

there is usually fe'fer when the condition is being

treated.

'.f)lia;-tever _.usually subsides after the

infection ia controlled by the sulfonamide.

is usually in about two or three days.

·.1•hia

�he fe•e�

due to the drug begins aeeere•iftg � .ttegemen and
Blake (28J and Mainzeer \29J between the seventh
and ninth day.

A rather distressing manifestation

1• the appearance 01' drug fever about four day•

after therapy baa b�en stopped.

One has difficulty

deciding whether the fever is due to the drug or
ia an exacerbation of the infection.
Brown, Thornton, and Wilson (23J believe that
drug fever 1a a useful sign of toxicity.

'i'hey state,

however, that it is not reliable since complications

can occur without it.
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Dermatoses.
The dermatoses are common toxic manifestations
of sulfonamide therapy.

Tedder, (31) in 1939 placed

these dernatoaea in thra� distinct types.

The

first and most common type 1a precipitated by ex
posure to sunlight.

In this type the level ot

sulfanilamide in th� blood is not abnormally high,

nor is there' ordinarily a sensitivity to the drug.

However, the combination ot factors occurring in

ternally, such as possible abnol'lllal porphyrin
metaboliaa, lowered resi�tance due to the disease
process and the irritative effects of the suns

rays, results in the occurrence of a localiz�d

dermatitis which may be ltOmpl�ca.ted by areas of

dermatitis at distant points.

�he second typ�

ot eruption is that in which d8finite sensitivity
to the drug occurs, resulting in.a sensitization
dermatitis.

The patient cannot tolerate further

sulfanilamide in any dose.

�he third type of

dermatitis is that resulting from poor tolera
tion ot, or saturation with sulfanilamide and
presenting the typical picture of toxic der
matitis.

The toxic effects of the drug r�ault
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f'rom improper utilization of the drug or from ita
gradual accum.ulat1on in the systea.

The patient

can tolerate further sulfanilamide therapy pro
viding the excretory functions are normally re
swned and the dosage is properly modified.

�here

is no tnown sensitivity to the drug in these cas�s.
�chlesinger and Mitchel (32) described what

tb�y called a natural history ot the reaction.
'l'he erup.tion itself appears in fi'Ye to se-Yenteen
days.

It may be preceded by a transient leuko

penia accompanied by a slight but definite
er1t�e:ma.

There is always a prodroma.l period

of' fever, three to se-.enty two hours, which con
tinues till the appearance of the eruption.

·J.·h•

eruption usually lasts from thirty six to ninety
'

six hours. ·occassionally there is a hemorrhagic
element.

After �ntervals, read.ministration of

the drug causes a totally different reac�ion.

�here is a leukocytosis, malaise, nausea, vomit

ing, headache and a scarlant1n1form rash which
fades in about twenty four hours.
large doses.

This is with

Small doses caus� a leukocytoais,

mild elevation o� temperature and a slight flush
ing.

26.
According to Long and Blias (3) the erup
tions resulting from the sulfonamides may be
angioneurot1e, edematous, erya1peloid, erythe
matous, extoliat1ng, morbi}litOHt-, petechial,
purpuric, pustular, scariatiniform or urtica
rial.

Volini, Levitt, and u•Neil (33, described

a nodular typ·e of eruption that resulted from ,.
sulfathiazole.
�ehwentker and uelman (34) in 1937 first
described the rash that occurred with sulfanil
amide.

They found that it occurred in 6% of the

cases.

:,:he eruption was distinctly :morb1111form·

in characte�, made up of maculo-papular lesions
which Wbre slightly raised and brownish red �-n
color.

'.l'h eae lesiona did not.. fade out .completely

when pressure was applied but the blanching was
considerably mor�-marked than that seen with
m�aslea. · �h� entire body was usually affected
with the rash, but in some cas�s the rash was
limited to the bu_ttocks and legs.

�n other cases

it was found on the palms and soles.

�he rash

was usually associated with fever and general
malaise and sometimes preceded the rash by
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seYeral hours.-

'l'he evolution of the raah usually

occupied about twelve hours.

when therapy was

discontinued th4:t rash disappeared in 48 hours-.
If therapy was started again a rash appeared again

but the second rash was scarlatiniform in charac
ter.

If therapy is continued after the appearance

of a raah the eruption disappears in about 72 houra.

Greenwood (35J found that rashes occurred in 2 to
6� of cases treated with and average d�se.

If the

patients were intensely treated eruptions occurred

in 30�.

Newman and Sharlit (36) in 1937 found that

sulfan�lam.ide could photoeeaai\1.,. ak.i.a by some

unknown mechanism.

They obse�ved that threshold

doses of the drug were necessary at the time of
eJtposure to sunlight to effect an eruption and

that on withdrawal of both drug and aualight the

eruption completely diaappeared be�ore:the

sensitising influence of the irradiation has been
dissipated.

Thia was proven by the fact that re

actiomr-�ould again be elicited in previously
inYolved akin by further exhibition of the drug
in the absence ot added irradiation.

The appear-
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ance in scattered, unexposed sites of nonde-

script erythemas siJllultaneoualy with the more
spectacular eruptions in the exposed areas sug
gested that in addition to the m,ainf'est cellular
baekground to the sensitizing mechanism involved,
there was possibly a concomitant hlDloral dis

turbance able to induce cutaneous changes at a
distance.

They tound the eruptions on the ex

posed alll'tace� to consist of red maculea and a
scarlatini.form:·ras:b. On withdrawal or the drug
and --1.1.ght the rash disappeared rapidly.
PaPk and Pl&tt-a-.- (37) in the Kiddle Ea.st
noted the same errects that Newman and Sharlit

did with the other sulfonamides.

They round

that the preaence of melanin was a protection
againat the eruption.

The bronzed parts or the

body were the least a.ffected by the drug.

Dermatitis is less·commonly found in therapy

with sulfapy�itli.Be tbaa s�lfanilamide.

In the

case of sulrathiazola it probabl.,1-�causes der

matoais more �equently than does sultanilamide
a�d.i� to Spink ( 2).
One of the rare types.of dermatoses that is

�.

tound with sultathiazole is angioneurotic edema.

Dennie (38) described a case which resulted in a
swollen face, closed eye lids, both hands and
arms showed severe edema.

The tongue was so

swollen that the patient could not talk.
Volini, Levitt, and O'Neil (33) described

the nodular type of eruption resulting from the
ua& ot sultathiazole.

They found that this

eruption followed a chronologic sequence.

It

a pparently begina with macules, then becomes pap
ular, and finally becomes nodular, depending on

the amount ot the drug administered, the continued
use of the drug and the age of the patient.

In

creasing age probably renders the patient-more

suceptible to cutaneous complications, eapecially
the aeverer forms.

The nodular torm has not been

encountered previously 1n any other disease or
condition.

They first appear on the extremities,

extensor surfaces of the hands and arms and the
tlexor surfaces ot the thigh.

The lesions occur

bilaterally but not symmetrically.

Initially the

nodules are diacrete but spread rapidly and may
involve the entire body.

They may remain discrete
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or !'use and become confluent.

They are elevat

ed above the skin and vary in d101eter rrom one
The color is dark reddish.

to ten millimeters.

Weinstein and Domm (39) in 1941 described

a case ot acute exfoliatiTe dermatitis that re
sulted in a fatality.

The rash resembled that ot

dermatitis exf'oliatiTa neonatorum.

The ratality

resulted atter administration of only 15 grams ot
aulrathiazole.

They believe the potential danger

ot sultathiazole dermatitis should be kept in
mind and on the first appearance of a cutaneous

eruption the drug should be withdrawn and fluide

forced.
· Wien and Lieberthal ( 40) in l94l reported

the development ot tense bullae on akin which was
apparently normal.

the mouth.

There were also bullae in

The toxic reaction tollowed,the use

ot sulfanilam1•e and sulfapyridine and produced

a generalized involvement ot the skin simulating

pemphigus.

With a generalized malordorous der

matitis with extol1at1on there was a development
on the trunk and extremities of tense bullae and
a septic picture.
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· Van Rooyen (41) reported the occurrenc� of
27 cases of herpes labialis after the use ot
aulfapyridine and T.A.B. vaccine.

This eruption

usually occurred two days •fter beginning the�n.
The herpes did not·appear when the vaccine was

omitted from the treatment.
Finland, Strauss, and Peterson (25) reported
the appearance of a rash in nine cases.

This

dermatitis resembled that produced by aultathia
zole.

Cole (42) reported the appearance of a der-

matitis reaulting from the use of sultaguanidine.
No reports of dermatitis have yet been reported
from the use of sulfaauxidine.
Treatment of the dermatosia may be both

prophylactic and therapeutic.

Some of the erup

tions ma.y be prevented by keeping the patient

from the direct rays of the sun.

After the erup

tions have appeared the treatment consists of
withdrawal of the drug, forcing of fluids and.

soothing lotions.
Strauss and Finland (ll,) used para amino

benzoic acid to prevent and treat the eruptions
ot the sulfonamides but the drug was

or no

value.
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Red Blood Cell D-,erasias.
One of the more serious toxic reactions of
the sulfonamides is the anemia that may result.
Watson and Spink (43) tound that in custo:11ary
dosages the sulfonamides usually cause an ac

celeration of the metabolism of hemoglobin

characterized by an increase of urob111nogen in
the feces and a varying increase in the retic
ulocyte percentage.

The·most marked acceleration

of hemoglobin metabolism is represented by the un

usual eases in which the outspoken hemolytic

anemia occurs.

Thia condition ia therefore to be

regarded as a much more marked d·egree of a usual
toxic effect of the drug.

The occurrence of

macrocyt1c or normocytic, mildly hypochromie

anemia after administration of the sulfonamides .,
indicates a disturbance in hemoglobin formation
in addition to increased hemolysis.

In many persons the administration of aulta
nilamlde in the usual doses is followed by some
evidence of dysfunction of the liver, such as

urob�linogenuria, elevation of the serum bili
rubin or jaundice.

The jaundice is, in part,
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of the regurgitation type, as is evidenced by the
frequent occurrence of a direct van den Bergh.
HarYey and Janeway (44-} in 1937 describea

·three cases of rapid hemolyaia during the adminis
tration of sulfanilamide.
tinge was noticed.

In all cases an ieteric

The hemoglobin dropped to less

than 40% in·all cases and the red blood cells
dropped to less than 2,225,000.

All the patients

became weak, drowsy, irrational and had-• f&ver,

Jennings �and SO'tlthw&-11-S•nder (45) confirmed the
findings and rapo.r�ed an abnormal activity of th•
marrow and a depression of erythropoiesis.

wood (46) in 1938 reported on 21 cases of
acute anemia resulting from therapy with sulta
nilamide.

He found that the earliest signs of

anemia appeared between 24 and 72 hours after the
onset of therapy.

The maximum anemia occurred

on the fi.tth day and in no case did it appear

before the third day or after the seventh day.
Four out of .five patients in whom acute an�mia
developed suf'fered a recurrence wh en a second
course ot the drug was g1Yen.
Koletsky (47) reported a fatality resulting
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from a hemolytic anemia produced by therapy with
sulfan1la m1de.

This followed a report by Wood on

a fatality from sulfanilamide.

A curious co

incidence was that both patients were reported to
be syphilitics.

The question was raised as to

alterations of the hem.opoietic mechanism incident
to syphilis being related to the fatal outcome.
Spence and Roberts (48) found a marked
erythropo1etic hyperplasia in the bone marrow that
was the usual response to peripheral blood des
�ruetion.

In their case there was a leukemoid

picture which they believe was due to �--.rk�d
bone marrow stimulation and hyperplasia.
Quick and Lord (49) in 1941 reported a case
of hemolytic anemia resulting from only seventy
grains of sulfathiazole.

This case presented

the same symptoms as those found in the other
sulfonamides.

Recovery resulted after a pro

longed stormy course.
A case of aplaatic anemia resulting from

therapy with sulfathiazole was reported by Meyer
and Perlmutter (50).

In this patient the hemo

globin dropped to 5 gm, the red cells to
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1,710,000 and the white cells to 1,600.

There

were purpurio spots on the entire body.

sternal

puncture showed a typical picture of an aplastic
anemia 1n the bone marrow.

The marrow was hypo

plaati� with a depression o� all cellular elements.
Cessation of therapy and repeated blood trans
fusions resulted in a recoYery of the bone marrow.
Thia would indicate that the process is not ir
reversible if it is discovered early.

An important factor in the treatment of

disease is the use of sulfonamides during preg
nancy.

The question of whether toxic �eactions

may occur in the fetus have been diacusaed by
Heckel (51).

He found that the concentration of

the sulfonamide was the aeme in the fetus .as in
the blood of the mother.

He reported a case in

which a hemolytic anemia resulted in the- child
after the mother had been treated.

recovered after a stormy course.

The child

Ginzler and

Cheaver (52) reported a death in a child froa
acup:e yellow atrophy of the liver following
aulfanilamide treatment 1n the mother.

They

also had a case of hemolytic anemia following
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treatment of the mother.

erythroblastosia fetal1s.

Both cases resembled

Kreinin (53) in his work found that the
blood of patients treated with sulfanilamide
did not distur the cross matching and could be
used for transfusions.

cells wa-s not altered.

The fragility of the

The treatment of the anemias resulting

from sulfonamide therapy is immediate with
drawal of the drug, sufficient blood by trans

fusion to decrease symptoma and intravenous
fluids.
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White Cell Changes.
After the sulfonamides have been used for

sometime a leukopenia usually results.

The white

cell count before treatment is usually higher

than normal and after treatment it drops to normal
or a little below the normal level.

No adequate

explanation can be found for this.

Shecket and Price (86) reported a case of

fatal granulocytopenia following sul.fanilamide
therapy.

The fundamental picture was that of a

toxic granulocytopenia with arrest.of the matur
ation of the blast forms of the myeloid aeries

such as has been reported with other toxic drugs.
This condition was not due to an idiosyncrasy
because of the quantity and the prolonged use of
the drug.

In all cases of granulocytopenia re

ported the administration of the drug was between
15 and 30 days with an average of 27 days.
Brown, Thornton, and Wilson (23) and Flippin,
Reinhold, and Schwartz (24) reported cases of
granulocytopenia resulting from the use of sulfapyridine and sulfathiazole.

In these cases there

was a decrease of the poly morphoneutrophils to

leaa than 50% •.
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Kennedy and Finland (55) reported

a

fatality

caused by agranuloc7tosis resulting from aulta
thiazole therapy.

After three weeks treatment

there was a complete absence of the granulocytes
and a marked drop in the other leukocytes in the

blood.

Rinkoff and Spring (56) believe that the

sulfonamides cause this by depressing the action
or the bone marrow and apparently act mainly by

arresting the maturation of the leukopoietic
elements.

The factor ia total dosage and not the

blood concentration for producing this condition.
Hayne. and Larimore (57) report·ed a fatality rrom.

agranulocytosis with sultathiazole which also re
sulted in a severe gangrenous and membranous
pharyngitis and laryngitis.

G-Oldman, Applebaum

and Antopol (58) reported a case ot malignant

neutropenia with complete bone marrow aplasia
due to the ;use of sultapyrid1ne.

Finland,

Strauss, and Peterson found a leukopenia in
sevwral cases treated with sulfadiazine.

Spicer,

Daft, Sebrell, and Asburn (59) demonstrated
agranuloeytosis and leukopenia, experimentally,
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in animals with sulfasuxidine and su1faguan1d1ne.
If an agranulocytosis d�velop■ the drug should
be decreased or stopped altogether if no response
occurs.

Care should be taken with children in the

administration of the sulfonamides according to
Str� (60).

He finds that infants and children

usually have a �pressed bone marrow by infection
and it would be very easy to produce a granulocyto
penia with small doses of the drug in a short time.
He believes that discontinuance ot the drug ia
adequate but pentonucleotide therapy accelerates
the rate of recoYery of the bone marrow.

r
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LiYer Complications.
Jaundice which ia associated with a marked
decrease in liver function and without acute hemo
lytic anemias in patients receiYing sulfanilamide
was observed by Long and Bliss (17).

Garvin (61)

followed these observations with the report of
five cases of toxic hepatitis after the use of
suU'anilamide.

Two of the patients became jaun

diced while taking the drug and the others became
jaundiced from four to thirty f1Ye days after the
therapy had been stopped.

With three of the cases

there was present an exfoliating type of dermati
tis.

All cases had a high 1cteric index, one had

ascites and in all the liver margin was two_ to six
centimeters below the costal margin. One of these
patients died while the others recovered after
stopping the sultanilamide.
A case of acute yellow atrophy of the liver
following sulfanilamide therapy was reported by
Cline (62).

This was a case of overdoaage.

The

patient was taking more sulfan1lam14e than the
physician prescribed.

Autop■y findings revealed

that the liver was small, had massive breaking up
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of the lobules and cords with the separation ot
the remaining-fragments into indiscriminate cell
groups.

The liver cells were beyond recognition

in most of the liver.

Bile pigment was scanty.

The brain; apleen, kidney showed pathological
findings also.
Berger and Applebaum (63) reported a case of
subacute atrophy of the liver in which there was a
beginning ci-rrho_sis, an extens1Vti necrosis, a re
placement tiorosis, and a toxic hepatitis.

Thia

patient also showed nausea, vomiting, Jaundice,.
enlarged liver and ascites.
Russell (64) reported what he called a toxic
necrosis of the liver.

In this patient there was

a disintegration of the liver cells.

The liver

showed several lesions.
Spink (2) found that hepatitis occurs less
with aultapyridine than it does with sultaniiamide.
Sultathiazole causes less hepatitis than does the

·•u�fapyridine. He suggests the use of the aulfa

th1azole whenever there is any indication of pre
vious l1Y6r damage.

Finland, Strauss, and

Peterson (25) found no jaundice in 466 patients
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treated with sulfadiazine.
Garvin (61) suggests as treatment for the
liver manifestations a withdrawal 0£ the drug,
glucose, transfusions, forcing fluids, emmol

lients, and symptomatic treatment.
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Renal Complications.

Renal symptoms have not resulted to any great ,
extent from the use of sultanilamide.

Allen (12)

r�ported a case in which symptoms resulted in an
already damaged kidney.

The symptoms which re

sulted were gastrointestinal and cerebral.

With the advent of sulfapyridine and sulfa

thiazole renal symptoms were observed.

Monto (65)

reported on the causes of renal complications.

He belieYed the condition• favoring the occurrence
or renal disiea.se wi.th 3"1J.::rtmam1d4i therapy w.ere ,prll
vious renal damage, toxicity of the disease, idio

syncrasy to the drug, the quantity of the drug .

given in a unit of time, th� general condition of

the patient and the sulfonamide used.

Sult'onamides

are toxic materials and may act on the kidneys in
a manner similar:to renal irritants producing toxic

nephritis.

A second 1ntrarenal lesion ia found in

those patients in whom a preexisting nephritis was

present and in whom reabsorption of the drug in the
convolute� tubules is faulty.

This results in an

increased concentration and desposition of the drug
in the tubules.

As for extrarenal lesions anuria
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has resulted from 1ntravascular hemolysis and plugg
ing of the ureters.
Graham et al. reported that four patients deTe
loped gross �ematuria, usually accompanied by ureter
al pain after the use of sul�apy�idine.

The cause

of the hematuria was not definitely determined,but
the presence of larg.&. numbers of j
. agged crystals
of sulfapyridine' in freshly voided urine was suggested as the cause.
Wilson and Billingaley (67) reported a case
of anuria resulting from obstruction of the lower
part of the ure_ters.

This they believe was probab

ly due to acetylated sulfapyridine.
Carson and smith (68) reported a case of
aultapyridine anuria in which. there was massive
despositions of acetylsatfap7:rfd1Be.1.:ln the:. p•lvis
and ureter leading to a hemorrhagic pyelitis and
ureter1t1s. _T�ey also found some glomerul•r and
tubular damage, which may or.may not have been due
to the direct action of the sulfapyridine or may
have been due to the secondary effect of the
obstruction.

The cases ot r�nal complications are

probably due to an idiosyncrasy causing th� form-
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at1on of a high percentage of the acetylated form
of the sultapyrid1ne.

The acetylated form ia only

half as. aoluble as the aultapyridine.
Renal complications due to sulfathiazole was
reported by Garvin (69).
of his cases treated.

He found crystals in 61.1%

In contrast sulfapyridine

crystals were found in the urin� in 28.6% of the
cases.

The incidence of hematuria with sulfa

thiazole was 14.8% _and 10.7% with sulfapyridine.
Anuria of the type found with sulfathiazole

and sulfapyridine resulted from sulfadiazine in a
case reported by Thompson, Harrell, and Brown (70).
Wright, and Kinsey (71) reported anur�a·1n 48% of
cases treated.

The factors involved were the

amount of the arug, blood level, duration of therapy
and urinary output and fluid intake.
A fatal anuria following sulfadiazine therapy
was reported by_ Hellwig and Reed (14}.

This case

was different in that the cause of the anuria was
due to a severe cellular degeneration of the con
voluted tubules and the ascending portion of Henles
loop.

The degeneration is similar to mercury

poisoning.

Hyaline easts and sulfadiazine crystals
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were found in the tubules.

Blood clots were

found in the renal pelves and the upper third of
the ureter.

In the anuria due to the other

sulfonamides the obstruction is found in the
lower third of the ureter.

The treatment of kidney complioationa,
according to Monto, consist of prophylaxis.

This

is adequate fluid intake, daily determi"Uation of
blood level of the drug, daily urinalysis in
search of albumin and red blood cells.

In case

of anuria, immediate catheterization of the ure
ters is indicated.

Discontinuance of the drus

and irrigation of the pelvis with warm saline
solution.

According to Spink (2), microscopic

hematuria is not an indication for discontin
uance of the drug but groas hematuria should
require suspension of therapy.
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Nervous Manifestations of Sultonarnides.
Kinor toxic aanifestations such as headache,
and dizziness haTe been caused by the sultanom.ides.
The dizziness may simulate that of alcholic intoxi
cation (3).

Little (72) found that mild deprea

sion and euphoria were the common manifestations
with sulfan1lamide.

A few more localized cerebral

effect.s may cause- peeuliar syndromes such as a
ease of severe dJsmorphosia.

In this case there

were &Mular and ourTilinear distortions so that
objects looked like images seen in the trick mir
rors of side shows.

Among the other a-ymptoma

found were disturbed distance perceptions, telopaia
and microps1a, aphasia, agraphi• and stammering.
Frank psychoses beginning three to ten days after
therapy was started had confuaion, disorientation,

depression, euphoria, auditory and visual hal
lucinosis and distractability.
were seen at timea.

Paranoid trends

It was difficult to say wheth

er the psychoaes was due to delerium. from the in
fection or to the chemotherapy.

A ease of peripheral neuritis was reported by
Ornsteen and Furst (73).

There was an increased
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muscle tenderness, numbness, paresthesia, and
partial loss of motor function ot the lower limbs
resulting in a waddling gait •. After withdrawal of
the drug and large doses of vitamin B the symptoms
disappeared.

Encephalomyelitis following sulfanilalllide

therapy was reported by Fisher (74).

The first case

was a picture of ascending myelitis and the other
was one of typical encephalomyelitis.

cending case death resulted.

In the as

The other case re

covered but all the reflexes did not disappear.

Autopsy findings showed a perivascular demyeli
nat1on, Yascular damage, and minute scattered
hemorrhages.

There is a picture of fibrinoid

necrosis and frequent leukocytic infiltration
of the walls.

In post infectious encephalomye

litia there are a few thromboaed vessels but no
inflammatory changes as is found in this ease.
There was also a massive softening ot the cord.
Roseman and Aring (75) reported a case of
encephalopathy from aultathiazole.

This case was

unique in that the pathological picture presented
here differs from the normal picture found in
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encephalomyelitis.

The pe.ri•ascular h&Jlllllorhages

were confined to.the gray matter of the cerebral
hemispheres and to the gray :matter of the brain
stem.

This localization is peculiar because

ordinarily the hemorrhages are found in the white
matter.

Jobnatone and Forgass (76) and Cutia and

Bowman (77) found restlessness, irritability, con
fusion and stupor to be the main nervous reactions
following aulfapy�idine.

The symptoms were more

pronounced a�ter intravenous therapy than oral

therapy.
A rather interesting toxic reaction from

sulfathiazole was reported by Watt (78).

He had

five cases of epilepsy following application of
sulfathiazole in proximity of the brain in the
frontal region.

EXperiment�lly this reaction

..

will occur with sulfathia:io1e but not with sulfa-

....
nilamide, ault'apyridine or

1t»'lt:adiazine.

Treatment of these nervous manifestations
depends on the ser1»u.-.s. of the condition.

If

a severe reaction results the drug should be dis
continued at once.

Fluid.a forced and large doses

50.
of vitamin B. given.

McGinty, Lewis, and Holtzclaw

(79) found that large doses of nicotinic acid dur
ing sulfonamide therapy produced a definite clinic
al change.

The most marked change _was the clearing

of mental apathy.

51.

Optic and Conjunctival Manifestations.

Bucy (80) reported a case of optic neuritis
that followed a single tablet, ot sultan1lamide.

He believed that this was a caae of idiosJncraay
and was also due to the sulfates that were given
with the drug.

4/�oo

The vision dropped to 6/200 and

in each eye.

Symptoms subsided rapidly on

withdrawal of the drug.
Hornbogen (81) reported a case in which a
blurring of vision resulted after the withdrawal
of the sult•nilamide.

His case was due, he be

lieves, to an edema of the lens.

The chemoais

of the bulbar conjunctiva in this case definite
ly indicates a change in the water balance of
the eye.

A toxic reaction that is produced only by

sulfa.thiazole is a conjunctivitis and scleritis .
Volini, Levitt and O'Neil (33) found that the

involvement of the conjuncti�a was usually with
cutaneous eruption.

It was frequently severe

with a bright red injection of the palpebral and
bulbar conjunctiva with edema of the eye lids

and a seropurulent discharge.

Soae photphobia

52.

was present.

The conjunctivitis cleared rapid

ly and no permanent changes were noted after
withdrawal of the drug.

53.

Intestinal Complicationa.
, Since the advent ot sulfonaaide drugs very
little has been said of intestinal complieationa.
Recently, Sutton (82) reported a case ot intestin
al obstruction that resulted from the use ot aulta
thiazole after an appendectomy.

The suilathiazole

proauoed a dense mass of adhesions around the ileum
which resulted in a kink with obstruction.

A red

dish granular looking tissue was found where the
sulfathiazole had been placed.
Another unuaual reaction was reported by
Crowley (83).

He had two cases ot intestinal

hemorrhage �hat resulted in children treated

with sultathiazole and sullapyridine.
patient died.

One

The children were being treated

for meningicoccic meningitis and the melena
could not be explained.

54.

· Myocardi tis.
A very interesting report was made by French
and Weller (84) on sulfonamides and myocarditis.
Excluding all cases at autopay that had a disease
that would cause a myocard1t1d and those cases of

slight infiltration they found that 55% of the

patients treated with sulfonamides had an eoa1no
phil1c myoearditia.

The age groupa of these cases

varied from one month to eighty seven years.

All

types of sulfonamides were used and the dosage

�anged from five to two hundred grams.

No myo

carditis was found in cases in which the drug had

been discontinued for more than thirty days prior
to death.

No macroscopic changes could be found.

Microscopic changes showed a cellular infiltration,
which was peri-vascular.

The myocarditis involved

both auricles and ventricles.

This finding raises the question of whether

the myocarditis will cause perm.anent '1amage or
whether it may cause other complications.

56.
Spermatogenesis.
In 1938, Jaubert and Motz reported that
sulfan1lam1de eauaed a marked reduction in the
nUlllber of normal sperm.

Thia was confirmed by

Mar ion and Vigoni ( 3) • .
Heckel and Hori (85) found that in cases
studied before and after* administration ot sulfa
nilamide there was no·demonstrable change in the
sperm count.

Summary.
1. A brief history of chemotherapy was presented.
2. The various theories of the eauae of the toxic
reactions were discussed.

No definite eonclu

■1ons were drawn as to the cause of these
reactions.
3. The toxic reactions that were discussed were
nausea, vomiting, cyanosis, aciaosis, headache,
dizzineas, drug fever, dermatitis, hepatic
damage, anftlia, agranuloeytosis, hermaturia,
a.nuria, visual diaturbances, nervous reactions,
intestinal obstruction and hemorrhage, and
spermatogenesis.
4. Factors whieh may help to produce the toxic
reactions are the nature of the infection, the
condition of the patient, the age of the patient,
the amount of drug given, sensitivity to the
drug, and diet and amount of flui4s taken.

5. Treatment consists of withdrawal or the drug,

forcing fluids, transfusions, bed rest, seda

tives, emollients and symptomatic treatment.

�. Prophylaxis consists of cheeking blood level
of the drug, daily urinalysis for hematuria
and albumin, forcing fluids, NPN level ana
icteric index of the blood, and daily ob
servation by the ph,sician.
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